What is William Blair's Forecast for Neogen FY2025 Earnings?

Neogen Co. (NASDAQ:NEOG - Free Report) - Equities research analysts at William Blair lowered their FY2025 earnings per share (EPS) estimates for shares of Neogen in a research note issued to investors on Thursday, April 10th. William Blair analyst B. Vazquez now anticipates that the company will post earnings of $0.32 per share for the year, down from their previous forecast of $0.38. The consensus estimate for Neogen's current full-year earnings is $0.38 per share. William Blair also issued estimates for Neogen's Q4 2025 earnings at $0.10 EPS and FY2026 earnings at $0.43 EPS.

Several other equities research analysts have also recently commented on NEOG. Guggenheim dropped their price target on shares of Neogen from $15.00 to $13.00 and set a "buy" rating on the stock in a research report on Thursday, April 10th. Piper Sandler dropped their target price on shares of Neogen from $13.00 to $6.50 and set a "neutral" rating on the stock in a report on Monday.

Neogen Price Performance

Shares of NASDAQ NEOG traded down $0.35 during mid-day trading on Monday, reaching $4.60. 8,248,769 shares of the company traded hands, compared to its average volume of 2,600,223. Neogen has a fifty-two week low of $3.87 and a fifty-two week high of $18.58. The company has a debt-to-equity ratio of 0.33, a current ratio of 3.77 and a quick ratio of 2.46. The stock has a fifty day simple moving average of $8.86 and a 200-day simple moving average of $11.81. The firm has a market cap of $997.94 million, a PE ratio of -2.10 and a beta of 1.57.

Remove Ads

Neogen (NASDAQ:NEOG - Get Free Report) last issued its quarterly earnings data on Wednesday, April 9th. The company reported $0.10 earnings per share for the quarter, missing analysts' consensus estimates of $0.12 by ($0.02). The company had revenue of $221.00 million for the quarter, compared to the consensus estimate of $225.27 million. Neogen had a negative net margin of 52.12% and a positive return on equity of 2.89%. Neogen's revenue for the quarter was down 3.4% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.12 earnings per share.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Norges Bank acquired a new stake in Neogen in the fourth quarter valued at approximately $212,171,000. Clarkston Capital Partners LLC acquired a new stake in Neogen in the 4th quarter valued at approximately $34,801,000. Vanguard Group Inc. increased its position in Neogen by 9.8% in the 4th quarter. Vanguard Group Inc. now owns 21,637,251 shares of the company's stock worth $262,676,000 after buying an additional 1,928,491 shares during the period. T. Rowe Price Investment Management Inc. lifted its holdings in shares of Neogen by 27.2% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 7,114,702 shares of the company's stock worth $86,373,000 after buying an additional 1,521,560 shares during the last quarter. Finally, Dimensional Fund Advisors LP boosted its position in shares of Neogen by 24.0% in the fourth quarter. Dimensional Fund Advisors LP now owns 6,939,984 shares of the company's stock valued at $84,254,000 after acquiring an additional 1,345,056 shares during the period. Institutional investors and hedge funds own 96.73% of the company's stock.

Insider Activity at Neogen

In other Neogen news, CEO John Edward Adent bought 23,035 shares of the stock in a transaction on Thursday, January 16th. The shares were bought at an average price of $11.03 per share, with a total value of $254,076.05. Following the purchase, the chief executive officer now directly owns 269,164 shares in the company, valued at $2,968,878.92. The trade was a 9.36 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CAO John Patrick Moylan bought 10,000 shares of the company's stock in a transaction dated Thursday, April 10th. The stock was acquired at an average price of $5.07 per share, for a total transaction of $50,700.00. Following the acquisition, the chief accounting officer now directly owns 10,000 shares in the company, valued at $50,700. This trade represents a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders purchased 47,835 shares of company stock worth $469,204 in the last quarter. 1.13% of the stock is owned by company insiders.

Neogen Company Profile

Neogen Corporation, together with its subsidiaries, engages in the development, manufacture, and marketing of various products and services dedicated to food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment offers diagnostic test kits and related products to detect dangerous and unintended substances in food and animal feed, including foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns; and AccuPoint Advanced rapid sanitation test to detect the presence of adenosine triphosphate, a chemical found in living cells, as well as provides genomics-based diagnostic technology and software systems that help testers to objectively analyze and store their results and perform analysis on the results from multiple locations over extended periods.